An observational study in Kawasaki Disease, Cardiovascular Disease and Anomalous Origin of Coronary Artery, sponsored by West China Second University Hospital. Enrolling by invitation at 1 site in China. Open to participants aged Up to 18 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-10-15.
Sponsored by West China Second University Hospital · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies in Mucocutaneous Lymph Node Syndrome with a site in China — 8 open to participants now, 8 under way, 2 of them phase 3. Mucocutaneous Lymph Node Syndrome · China.
Among the 16 studies in Mucocutaneous Lymph Node Syndrome with a site in China, this one is one of 2 that started in 2024, is one of 8 observational ones, and was the 10th registered.
62 studies on the registry are indexed under Mucocutaneous Lymph Node Syndrome; 17 are open to participants now.
Browse Mucocutaneous Lymph Node Syndrome studies →8 of the 16 studies in Mucocutaneous Lymph Node Syndrome with a site in China are open now. Recruiting first, the newest first:
Children's Hospital of Fudan University · Sites in China
Ages 2–18
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine · Sites in China
Ages 0–18 · Healthy volunteers
Children's Hospital of Fudan University · Sites in China
Ages 2–18
Children's Hospital of Fudan University · Sites in China
Ages 1 mo–18 yrs
Children's Hospital of Fudan University · Sites in China
Ages 2–18
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 12 Mucocutaneous Lymph Node Syndrome studies recruiting now, 1 (8%) sets no upper age limit and 11 (92%) stop at 75 or younger; 12 take children under 18; 2 take healthy volunteers.
This study: Up to 18 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 1 · Phase 3 6 · Phase 4 2
First in 2013; this study’s year is marked. 2 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 240 is below the median of 284 across 24 observational studies indexed under Mucocutaneous Lymph Node Syndrome.
Median enrollment 65 across the 8 interventional studies, 650 across the 8 observational. Of the 6 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 16 has an industry lead sponsor. The 5 most frequent:
West China Second University Hospital is the lead sponsor of 38 studies on the registry; 22 are open to participants now.
West China Second University Hospital has 2 studies filed under Mucocutaneous Lymph Node Syndrome — fewer than ten, so there is no comparison to draw.
4 of the studies in Mucocutaneous Lymph Node Syndrome with a site in China that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07530640Phase 3Children's Hospital of Fudan UniversityStatins Study in Children of Acute Kawasaki Disease With Coronary Artery Abnormalities | 2027-08-31 |
| NCT07686770Phase 3Children's Hospital of Fudan UniversityEfficacy and Safety of Immunoglobulin Plus Firsekibart in Patients With Kawasaki Disease | 2027-09-01 |
| NCT07405658Xinhua Hospital, Shanghai Jiao Tong University School of MedicineClinical Study on an Artificial Intelligence-Assisted Chest Radiograph Model Based on Big Data and Deep Learning for Early Detection of Kawasaki Disease | 2026-12-31 |
| NCT05643651Children's Hospital of Fudan UniversityRivaroxaban for Children Aged Over 2 Years With Giant Coronary Artery Aneurysms After Kawasaki Disease | 2027-06-01 |
Add all 4 to your calendar (.ics) → With an account.
Among the 16 studies in Mucocutaneous Lymph Node Syndrome with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
the goal of this observational study is to evaluate myocardial ischemia and myocardial microcirculation dysfunction in children with cardiovascular disease by myocardial stress perfusion imaging.
During their disease progress, participants will undergo myocardial stress perfusion, laboratory tests when hospitalization and follow-up, and the baseline data will be collected in the admission. all the above examination data will be analysed to identify early subclinical myocardial changes and evaluate the value of magnetic resonance myocardial stress perfusion in predicting prognosis.
From September 2024 to Jaunary 2034, pediatric patients diagnosed with cardiovascular disease were prospectively recruited from West China Second University Hospital, Sichuan University.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients diagnosed with cardiovascular disease, including Kawasaki disease, anomalous origin of coronary artery, postoperative congenital heart diseases
Major adverse cardiovscualr events
Major adverse cardiovascular events including cardiac death, transient ischemic attack or stroke, myocardial infarction, arrhythmia, heart failure, severe valvular disease, percutaneous coronary intervention, coronary artery bypass graft, and other cardiovascular surgery.
Time frame: 10 years after the onset
Plan to share: Undecided
Started Sep 2024 (actual). Primary completion is estimated for Jan 2034, 112 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Mucocutaneous Lymph Node Syndrome →
West China Second University Hospital